Applied Therapeutics (APLT) Stock Statistics & Valuation Metrics

Applied Therapeutics has a market cap or net worth of $43.24M. The enterprise value is $1.13B.

Applied Therapeutics has 116,356,476 shares outstanding. The number of shares has decreased by -2.65% in one year.

Applied Therapeutics’s return on equity (ROE) is -1.85 and return on invested capital (ROIC) is 0.00%.

The current PE Ratio of Applied Therapeutics is -1.13. Applied Therapeutics’s PEG ratio is 0.02.

In the last 12 months, Applied Therapeutics had revenue of 455.00K and earned -105.62M in profits. Earnings per share was -0.76.

In the last 12 months, operating cash flow was -81.84M and capital expenditures 0.00, giving a free cash flow of -81.84M billion.

Applied Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Applied Therapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.

Applied Therapeutics as a current ratio of 3.06, with Debt / Equity ratio of 33.45%

In the past 12 months, Applied Therapeutics has paid -105.62M in taxes.

Applied Therapeutics EV to EBITDA ratio is -0.41, with an EV/FCF ratio of -0.51.

Applied Therapeutics has $98.87M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$96.90M billion.

Gross margin is 378.67%, with operating margin of -22922.86%, and net profit margin of -23214.07%.

The average price target for Applied Therapeutics is $2.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy